You need JavaScript to view this

In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9

Abstract

Highlights: • Established CRISPR/Cas9 targeting promoter of HPV 16 and targeting E6, E7 transcript. • CRISPR/Cas9 resulted in accumulation of p53 and p21, reduced the proliferation of cervical cancer cells. • Finding inhibited tumorigenesis and growth of mice incubated by cells with CRISPR/Cas9. • CRISPR/Cas9 will be a new treatment strategy, in cervical and other HPV-associated cancer therapy. - Abstract: Deregulated expression of high-risk human papillomavirus oncogenes (E6 and E7) is a pivotal event for pathogenesis and progression in cervical cancer. Both viral oncogenes are therefore regarded as ideal therapeutic targets. In the hope of developing a gene-specific therapy for HPV-related cancer, we established CRISPR/Cas9 targeting promoter of HPV 16 E6/E7 and targeting E6, E7 transcript, transduced the CRISPR/Cas9 into cervical HPV-16-positive cell line SiHa. The results showed that CRISPR/Cas9 targeting promoter, as well as targeting E6 and E7 resulted in accumulation of p53 and p21 protein, and consequently remarkably reduced the abilities of proliferation of cervical cancer cells in vitro. Then we inoculated subcutaneously cells into nude mice to establish the transplanted tumor animal models, and found dramatically inhibited tumorigenesis and growth of mice incubated by cells with CRISPR/Cas9 targeting (promoter+E6+E7)-transcript. Our results may provide evidence for application of  More>>
Authors:
Zhen, Shuai; [1]  Xijing Hospital, Fourth Military Medical University, Xi’an (China); Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850 (China); Kyoto University, Kyoto 606-8507 (Japan)]; Hua, Ling; [2]  Takahashi, Y.; Narita, S.; [3]  Liu, Yun-Hui; [2]  Li, Yan [4] 
  1. Baoji Maternal and Child Health Hospital, 2 Xinjian Road East, WeiBin District, Baoji City, 721000, Shanxi Province (China)
  2. Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850 (China)
  3. Kyoto University, Kyoto 606-8507 (Japan)
  4. Baoji Hospital of Traditional Chinese Medicine, No 43, BaoFu Road, Baoji City, Shanxi Province (China)
Publication Date:
Aug 08, 2014
Product Type:
Journal Article
Resource Relation:
Journal Name: Biochemical and Biophysical Research Communications; Journal Volume: 450; Journal Issue: 4; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Subject:
60 APPLIED LIFE SCIENCES; CELL PROLIFERATION; HUMAN POPULATIONS; IN VITRO; IN VIVO; INHIBITION; MICE; NEOPLASMS; ONCOGENES; PATHOGENESIS; PROTEINS; THERAPY; TRANSPLANTS; TUMOR CELLS
OSTI ID:
22416689
Country of Origin:
United States
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 0006-291X; CODEN: BBRCA9; Other: PII: S0006-291X(14)01228-5; TRN: US15R1310122581
Availability:
Available from http://dx.doi.org/10.1016/j.bbrc.2014.07.014
Submitting Site:
USN
Size:
page(s) 1422-1426
Announcement Date:
Jan 05, 2016

Citation Formats

Zhen, Shuai, Xijing Hospital, Fourth Military Medical University, Xi’an (China), Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850 (China), Kyoto University, Kyoto 606-8507 (Japan)], Hua, Ling, Takahashi, Y., Narita, S., Liu, Yun-Hui, and Li, Yan. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. United States: N. p., 2014. Web. doi:10.1016/J.BBRC.2014.07.014.
Zhen, Shuai, Xijing Hospital, Fourth Military Medical University, Xi’an (China), Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850 (China), Kyoto University, Kyoto 606-8507 (Japan)], Hua, Ling, Takahashi, Y., Narita, S., Liu, Yun-Hui, & Li, Yan. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. United States. doi:10.1016/J.BBRC.2014.07.014.
Zhen, Shuai, Xijing Hospital, Fourth Military Medical University, Xi’an (China), Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850 (China), Kyoto University, Kyoto 606-8507 (Japan)], Hua, Ling, Takahashi, Y., Narita, S., Liu, Yun-Hui, and Li, Yan. 2014. "In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9." United States. doi:10.1016/J.BBRC.2014.07.014. https://www.osti.gov/servlets/purl/10.1016/J.BBRC.2014.07.014.
@misc{etde_22416689,
title = {In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9}
author = {Zhen, Shuai, Xijing Hospital, Fourth Military Medical University, Xi’an (China), Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850 (China), Kyoto University, Kyoto 606-8507 (Japan)], Hua, Ling, Takahashi, Y., Narita, S., Liu, Yun-Hui, and Li, Yan}
abstractNote = {Highlights: • Established CRISPR/Cas9 targeting promoter of HPV 16 and targeting E6, E7 transcript. • CRISPR/Cas9 resulted in accumulation of p53 and p21, reduced the proliferation of cervical cancer cells. • Finding inhibited tumorigenesis and growth of mice incubated by cells with CRISPR/Cas9. • CRISPR/Cas9 will be a new treatment strategy, in cervical and other HPV-associated cancer therapy. - Abstract: Deregulated expression of high-risk human papillomavirus oncogenes (E6 and E7) is a pivotal event for pathogenesis and progression in cervical cancer. Both viral oncogenes are therefore regarded as ideal therapeutic targets. In the hope of developing a gene-specific therapy for HPV-related cancer, we established CRISPR/Cas9 targeting promoter of HPV 16 E6/E7 and targeting E6, E7 transcript, transduced the CRISPR/Cas9 into cervical HPV-16-positive cell line SiHa. The results showed that CRISPR/Cas9 targeting promoter, as well as targeting E6 and E7 resulted in accumulation of p53 and p21 protein, and consequently remarkably reduced the abilities of proliferation of cervical cancer cells in vitro. Then we inoculated subcutaneously cells into nude mice to establish the transplanted tumor animal models, and found dramatically inhibited tumorigenesis and growth of mice incubated by cells with CRISPR/Cas9 targeting (promoter+E6+E7)-transcript. Our results may provide evidence for application of CRISPR/Cas9 targeting HR-HPV key oncogenes, as a new treatment strategy, in cervical and other HPV-associated cancer therapy.}
doi = {10.1016/J.BBRC.2014.07.014}
journal = {Biochemical and Biophysical Research Communications}
issue = {4}
volume = {450}
journal type = {AC}
place = {United States}
year = {2014}
month = {Aug}
}